Testing bumetanide for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mild cognitive issues or mild dementia caused by Alzheimer's disease.
- Your Alzheimer's medications should stay the same during the study.
- You must be able to have an MRI scan and complete memory tests.
- You cannot have serious liver or kidney problems.
- Your high blood pressure must be well controlled.
- You cannot be taking certain drugs like lithium, or medications that can harm your ears or kidneys.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This trial tests a drug called masitinib to see if it can help people with mild Alzheimer's disease. You'd get either the drug or a placebo, and doctors will check if your daily living skills and memory slow their decline.
This study tests whether a daily pill (tadalafil, a type of medicine usually used for blood pressure or erectile dysfunction) can help people with early Alzheimer's or mild memory problems. It aims to see if this drug can improve memory and slow down the disease, with the help of regular checkups and brain scans.
This study tests a non-invasive brain stimulation method (temporal interference stimulation) to see if it can improve memory in people with early signs of Alzheimer's disease. It aims to understand how the stimulation affects brain function.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.